Prevail Therapeutics Inc.
DelistedCIK 1714798fmd_0T1PA9RN6PFKAWWKW3HAT0V7ERManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Sep 30, 2020, 10 periods
| Line item | FY2018 | FY2019 |
|---|---|---|
| Research and development | 14 | 49 |
| Operating income | (19) | (66) |
| Interest expense | 0 | – |
| Interest and investment income | 1 | 3 |
| Other non-operating income (expense) | (0) | 3 |
| Net income | (19) | (63) |